


## Azimilide

<b>Cat. No.:</b>	HY-18600
<b>CAS No.:</b>	149908-53-2
<b>Molecular Formula:</b>	C <sub>23</sub> H <sub>28</sub> ClN <sub>5</sub> O <sub>3</sub>
<b>Molecular Weight:</b>	457.95
<b>Target:</b>	Potassium Channel
<b>Pathway:</b>	Membrane Transporter/Ion Channel
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

#### Description

Azimilide (NE-10064) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in *Xenopus* oocytes. IC<sub>50</sub> value: Target: in vitro: Azimilide blocked HERG channels at 0.1 and 1 Hz with IC<sub>50</sub>s of 1.4 μM and 5.2 μM respectively. Azimilide blockade of HERG channels expressed in *Xenopus* oocytes and I(Kr) in mouse AT-1 cells was decreased under conditions of high [K<sup>+</sup>]<sub>e</sub>, whereas block of slowly activating I(Ks) channels was not affected by changes in [K<sup>+</sup>]<sub>e</sub> [1]. Azimilide suppressed the following currents (K<sub>d</sub> in parenthesis): I(Kr) (< 1 μM at -20 mV), I(Ks) (1.8 μM at +30 mV), L-type Ca current (17.8 μM at +10 mV), and Na current (19 μM at -40 mV). Azimilide was a weak blocker of the transient outward and inward rectifier currents (K<sub>d</sub> ≥ 50 μM at +50 and -140 mV, respectively). Azimilide blocked I(Kr), I(Ks), and I<sub>Na</sub> in a use-dependent manner. Furthermore, azimilide reduced a slowly inactivating component of Na current that might be important for maintaining the action potential plateau in canine ventricular myocytes [2]. In guinea pig ventricular myocytes, NE-10064 (0.3-3 μM) significantly prolonged action potential duration (APD) at 1 Hz. At 3 Hz, NE-10064 (0.3-1 μM) increased APD only slightly, and at 10 μM decreased APD and the plateau potential. NE-10064 potently blocked the rapidly activating component of the delayed rectifier, I(Kr) (IC<sub>50</sub> 0.4 μM), and inhibited I(Ks) (IC<sub>50</sub> 3 μM) with nearly 10-fold less potency [3]. In vivo: NE-10064 (10 mg/kg intravenously, i.v.) reduced (p < 0.05) the incidence (8 of 12) of PES-induced ventricular tachycardia (VT). The cycle length of induced VT was not prolonged by NE-10064 (0.245 ± 0.046 s predrug vs. 0.301 ± 0.060 s postdrug). NE-10064 increased ventricular effective refractory period (VERP 166 ± 5 ms predrug vs. 194 ± 13 ms postdrug, p = 0.013), prolonged QTc interval (310 ± 12 ms predrug vs. 350 ± 16 ms postdrug, p = 0.004) and prolonged the effective refractory period (ERP) of noninfarcted myocardium (p = 0.045) [4].

### CUSTOMER VALIDATION

- Biochem Biophys Res Commun. 2016 Apr 29;473(2):396-402.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

### REFERENCES

- [1]. Busch AE, et al. Blockade of HERG channels by the class III antiarrhythmic azimilide: mode of action. *Br J Pharmacol.* 1998 Jan;123(1):23-30.
- [2]. Yao JA, et al. Azimilide (NE-10064) can prolong or shorten the action potential duration in canine ventricular myocytes: dependence on blockade of K, Ca, and Na

---

channels. J Cardiovasc Electrophysiol. 1997 Feb;8(2):184-98.

[3]. Fermini B, et al. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol. 1995 Aug;26(2):259-71.

[4]. Black SC, et al. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol. 1993 Dec;22(6):810-8.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA